Cover Image

Differentiated treatment of multi-resistant Gram-negative pathogens in intensive care units

Multi-resistant Gram-negative pathogens will pose an enormous challenge to medicine in the coming years. Therefore, the World Health Organization emphasises that there is a great need for the development of new antimicrobial drugs. At the same time, intensivists must be prepared to treat complex inf...

Full description

Saved in:
Bibliographic Details
Main Authors: Schmoch, Thomas (Author) , Heininger, Alexandra (Author) , Richter, Daniel (Author) , Brenner, Thorsten (Author) , Weigand, Markus A. (Author)
Format: Article (Journal)
Language:German
English
Published: September 2021
In: Anästhesiologie & Intensivmedizin
Year: 2021, Volume: 62, Pages: 398-409
ISSN:1439-0256
DOI:10.19224/ai2021.398
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.19224/ai2021.398
Verlag, lizenzpflichtig, Volltext: https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DynamicDOIArticle&SrcApp=WOS&KeyAID=10.19224%2Fai2021.398&DestApp=DOI&SrcAppSID=F2SIIFIUYl9XpoPqogV&SrcJTitle=ANASTHESIOLOGIE+%26+INTENSIVMEDIZIN
Get full text
Author Notes:T. Schmoch, A. Heininger, D. Richter, T. Brenner, M.A. Weigand
Description
Summary:Multi-resistant Gram-negative pathogens will pose an enormous challenge to medicine in the coming years. Therefore, the World Health Organization emphasises that there is a great need for the development of new antimicrobial drugs. At the same time, intensivists must be prepared to treat complex infections with multi-resistant pathogens more often. As a consequence, a sound knowledge of the resistance mechanisms and the available antimicrobial drugs is essential. In this context, new beta-lactam antibiotics (and combinations), such as ceftolozane / tazobactam or ceftazidime / avibactam, but also the combinations of / with meropenem / vaborbactam, aztreonam / avibactam or imipenem / cilastatin / relebactam, should be mentioned. Their availability is to be welcomed, especially with regard to their reduced toxicity in comparison to colistin-based therapies. Moreover, this review comments on cefiderocol, a new drug which could revolutionise the treatment of multi-resistant Gram-negative germs. This review article intends to give the reader an overview of the resistance mechanisms prevalent in Germany and the respective appropriate treatment options.
Item Description:Gesehen am 03.11.2021
Physical Description:Online Resource
ISSN:1439-0256
DOI:10.19224/ai2021.398

Similar Items